95 related articles for article (PubMed ID: 15069691)
1. Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy.
Kedar I; Mermershtain W; Ivgi H
Int J Cancer; 2004 Jun; 110(2):260-5. PubMed ID: 15069691
[TBL] [Abstract][Full Text] [Related]
2. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.
Blay JY; Negrier S; Combaret V; Attali S; Goillot E; Merrouche Y; Mercatello A; Ravault A; Tourani JM; Moskovtchenko JF
Cancer Res; 1992 Jun; 52(12):3317-22. PubMed ID: 1596890
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
Amato RJ; Malya R; Rawat A
Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
[TBL] [Abstract][Full Text] [Related]
4. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.
Walther MM; Johnson B; Culley D; Shah R; Weber J; Venzon D; Yang JC; Linehan WM; Rosenberg SA
J Urol; 1998 Mar; 159(3):718-22. PubMed ID: 9474133
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
Amato RJ; Morgan M; Rawat A
Cancer; 2006 Apr; 106(7):1498-506. PubMed ID: 16475152
[TBL] [Abstract][Full Text] [Related]
6. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM
Urology; 2004 Jun; 63(6):1061-5. PubMed ID: 15183950
[TBL] [Abstract][Full Text] [Related]
9. Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy.
Lauerová L; Dusek L; Simícková M; Rovný F; Spurný V; Rovný A; Slampa P; Zaloudík J; Rejthar A; Wotke J; Kovarík J
Neoplasma; 1999; 46(3):141-9. PubMed ID: 10613588
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
Daliani DD; Papandreou CN; Thall PF; Wang X; Perez C; Oliva R; Pagliaro L; Amato R
Cancer; 2002 Aug; 95(4):758-65. PubMed ID: 12209719
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843
[TBL] [Abstract][Full Text] [Related]
13. Application of thalidomide/interleukin-2 in immunochemotherapy-refractory metastatic renal cell carcinoma.
Schrader AJ; Heidenreich A; Hegele A; Olbert P; Ohlmann CH; Varga Z; von Knobloch R; Hofmann R
Anticancer Drugs; 2005 Jun; 16(5):581-5. PubMed ID: 15846124
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide for recurrent renal-cell cancer in a 40-year-old man.
Amato R
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 13):33-6. PubMed ID: 11204672
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of thalidomide and interleukin-2 in patients with metastatic renal cell carcinoma.
Olencki T; Malhi S; Mekhail T; Dreicer R; Elson P; Wood L; Bukowski RM
Invest New Drugs; 2006 Jul; 24(4):321-6. PubMed ID: 16683075
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of thalidomide in advanced metastatic renal cell carcinoma.
Minor DR; Monroe D; Damico LA; Meng G; Suryadevara U; Elias L
Invest New Drugs; 2002 Nov; 20(4):389-93. PubMed ID: 12448656
[TBL] [Abstract][Full Text] [Related]
17. Relation of prenephrectomy CD profiles and serum cytokines to the disease outcome and response to IFN-alpha/IL-2 therapy in renal cell carcinoma patients.
Lauerová L; Dusek L; Spurny V; Simicková M; Rovny A; Rejthar A; Kocák I; Kovarík J
Oncol Rep; 2001; 8(3):685-92. PubMed ID: 11295103
[TBL] [Abstract][Full Text] [Related]
18. [Significance of plasma interleukin-6 in the diagnosis of renal cell carcinoma].
Kamemoto H
Hinyokika Kiyo; 1993 Apr; 39(4):301-6. PubMed ID: 8503325
[TBL] [Abstract][Full Text] [Related]
19. Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors.
Guida M; Casamassima A; Monticelli G; Quaranta M; Colucci G
J Transl Med; 2007 Oct; 5():51. PubMed ID: 17953739
[TBL] [Abstract][Full Text] [Related]
20. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
